Clinical Trials Logo

Adiposity clinical trials

View clinical trials related to Adiposity.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03631680 Terminated - Adiposity Clinical Trials

The Role of Estrogen in Adipocyte Remodeling Following Surgical Menopause

RESUME
Start date: September 25, 2018
Phase:
Study type: Observational

The overarching aim of this study is to assess the downstream effects of abrupt estrogen deficiency in women undergoing elective bilateral oophorectomy by studying: 1. the rate of in vivo adipogenesis in the subcutaneous abdominal (scABD) and subcutaneous femoral (scFEM) adipose tissue depots following bilateral oophorectomy surgery using an innovative (and tested) 8-week incorporation of stable isotope (deuterium; 2H) administered in the form of heavy water (2H2O) to endogenously label adipose tissue DNA; 2. the changes in expression of subcutaneous adipose tissue genes and proteins specific to adipocyte expansion and function; extracellular matrix remodeling and fibrosis; and inflammation in the scABD and scFEM depots before and after elective bilateral oophorectomy.

NCT ID: NCT03582956 Terminated - Adiposity Clinical Trials

Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes

T1D
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effects of adiposity on resistance to insulin's ability to suppress hepatic glucose production and to stimulate peripheral glucose metabolism in adolescents with type 1 diabetes. In addition, this study will also examine the role of fatty liver disease on the insulin resistance of obesity in adolescents with type 1 diabetes.

NCT ID: NCT03115385 Terminated - Adiposity Clinical Trials

Probiotics and the Gut Microbiome in Obese Hispanic Youth

Start date: May 30, 2015
Phase: N/A
Study type: Interventional

This study will recruit 40 obese Hispanic youth (12 - 18 years of age who are greater than or equal to Tanner stage 4) from hospitals, clinics, and community centers. Participants will be randomly assigned to 16 weeks of probiotics (3 packets/day of VSL#3) or matched placebo. The purpose of this study is to demonstrate through a proof-of-concept trial that probiotics have the potential to alter the gut microbiome and gut hormones.